We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3001
MarketWise
MKTW
$51.7M
| $83K | ﹤0.01% |
+504
| New | +$98K |
|
|
TLIS
3002
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
| $79K | ﹤0.01% |
839
-26
| -3% | -$3.46K |
|
|
CSPR
3003
DELISTED
Casper Sleep Inc.
CSPR
| $78K | ﹤0.01% |
18,346
+541
| +3% | +$3.24K |
|
3004
Disc Medicine
IRON
$2.97B
| $76K | ﹤0.01% |
625
-21
| -3% | -$2.87K |
|
|
PPTA
3005
Perpetua Resources
PPTA
$3.07B
| $76K | ﹤0.01% |
15,174
+470
| +3% | +$2.62K |
|
|
AUO
3006
DELISTED
AU Optronics Corp
AUO
| $76K | ﹤0.01% |
+12,053
| New | +$76K |
|
|
TLMD
3007
DELISTED
SOC Telemed, Inc. Class A Common Stock
TLMD
| $74K | ﹤0.01% |
32,941
+3,411
| +12% | +$12.3K |
|
3008
NLI Holdings
NL
$307M
| $72K | ﹤0.01% |
12,451
-50
| -0.4% | -$314 |
|
3009
Summit Therapeutics
SMMT
$11.1B
| $67K | ﹤0.01% |
13,426
+908
| +7% | +$6.52K |
|
|
MBII
3010
DELISTED
Marrone Bio Innovations, Inc.
MBII
| $66K | ﹤0.01% |
72,939
-4,335
| -6% | -$5.22K |
|
3011
Turkcell
TKC
$4.8B
| $65K | ﹤0.01% |
+14,930
| New | +$68.9K |
|
3012
Itaú Unibanco
ITUB
$89.2B
| $64K | ﹤0.01% |
+16,753
| New | +$68.6K |
|
3013
Ambev
ABEV
$46.7B
| $58K | ﹤0.01% |
+20,890
| New | +$66.1K |
|
3014
Nomura Holdings
NMR
$29.1B
| $57K | ﹤0.01% |
+11,606
| New | +$58K |
|
|
STON
3015
DELISTED
StoneMor Inc.
STON
| $57K | ﹤0.01% |
23,060
+2,840
| +14% | +$7.29K |
|
|
KLDO
3016
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $57K | ﹤0.01% |
10,375
-467
| -4% | -$2.9K |
|
|
PLM
3017
DELISTED
PolyMet Mining Corp.
PLM
| $51K | ﹤0.01% |
16,794
+2,580
| +18% | +$8.6K |
|
3018
ReWalk Robotics
LFWD
$20.3M
| $47K | ﹤0.01% |
368
+106
| +40% | +$13.2K |
|
|
BLRX
3019
BioLineRX
BLRX
$12.1M
| $40K | ﹤0.01% |
364
+22
| +6% | +$2.61K |
|
3020
Transocean
RIG
$5.97B
| $39K | ﹤0.01% |
10,279
-6,028
| -37% | -$21.9K |
|
|
NH
3021
DELISTED
NantHealth, Inc
NH
| $35K | ﹤0.01% |
1,464
+93
| +7% | +$2.8K |
|
3022
UTStarcom
UTSI
$23.7M
| $16K | ﹤0.01% |
+3,473
| New | +$18.4K |
|
3023
Credicorp
BAP
$30.9B
| – | – |
-1,884
| Closed | -$228K |
|
|
BELFB
3024
Bel Fuse Inc Class B
BELFB
$4.25B
| – | – |
-20,284
| Closed | -$292K |
|
3025
Bassett Furniture
BSET
$177M
| – | – |
-8,961
| Closed | -$218K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.